Ono Pharmaceutical

CompanyJapanFounded 1947

Ono Pharmaceutical develops 2 assets, the furthest approved (sitagliptin in diabetes mellitus). Mostly small molecule acting on Insulin/IGF-1 signalling and DPP4; based in Japan, founded in 1947.

2
Assets
Furthest: Approved; 20
Trials: 0
Signals

Pipeline

sitagliptin
Dipeptidyl peptidase-4 (DPP-4) inhibitor increasing active incretin hormone levels
Approved, Small molecule, Insulin/IGF-1 signalling, DPP4, diabetes mellitus, type 2 diabetes
ONO-2808
Investigational therapeutic agent for the treatment of multiple system atrophy.
Phase 2, Small molecule, multiple system atrophy

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

Evidence behind the mechanisms3
Trials39
Similar companies6

Updated 11 Oct 2026 · 72 sources